UNSPSC 51282529: Cefazaflur sodium

This classification denotes the sodium form of a cephalosporin antibiotic with the molecular structure C13H13F3N6O4S3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 97I0692RNT chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(((1-methyl-1h-tetrazol-5-yl)thio)methyl)-8-oxo-7-((((trifluoromethyl)thio)acetyl)amino)-, (6r-trans)-, but more commonly known as cefazaflur, which bears US NIH Compound Identifier 40239.

UNSPSC 51282529 Cefazaflur sodium is a Commodity code tracking procurement of a specific pharmaceutical active ingredient; however, the recent state and local opportunities tagged to this code show no activity aligned with cefazaflur sodium itself. The Illinois Department of Public Health's August 2026 piggyback pharmaceutical contract through MMCAP Infuse awarded to Chartwell Rx LLC covered Doxycycline Hyclate 100mg tablets and Ciprofloxacin Hydrochloride 500mg tablets, and Seminole County, Florida's June 2026 IFB for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually solicited emergency-response medications and harm-reduction equipment. Neither opportunity involved cefazaflur sodium. State and local procurement under this code appears dormant or misclassified in current databases; the opportunities present indicate broader pharmaceutical procurement across state health departments and county community health programs, but not the specific active pharmaceutical ingredient named in the code.

The geographic footprint of recent activity spans Florida and Illinois, with issuing bodies limited to a state health department and a county health program. The Illinois contract, a completed IFB award with a total value of $2,999,999.11 over three years including renewals, supplied antibiotics for public health stockpiling. The Seminole County solicitation, posted June 30, 2026 with a July 26, 2023 response deadline (a date inconsistency in the source), sought quarterly deliveries of naloxone and drug deactivation systems on a two-year term with a one-year renewal option. Neither opportunity explicitly mentions cefazaflur sodium or cephalosporin-class drugs, suggesting a significant mismatch between the UNSPSC code designation and actual purchasing activity in the state and local market.